Strata Skin Sciences, Inc. (NASDAQ:SSKN) Sees Significant Increase in Short Interest

Strata Skin Sciences, Inc. (NASDAQ:SSKN) was the target of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 679,358 shares, an increase of 89.2% from the January 29th total of 358,994 shares. Based on an average daily trading volume, of 895,841 shares, the short-interest ratio is currently 0.8 days. Approximately 19.5% of the company’s shares are short sold. Approximately 19.5% of the company’s shares are short sold. Based on an average daily trading volume, of 895,841 shares, the short-interest ratio is currently 0.8 days.

Hedge Funds Weigh In On Strata Skin Sciences

A hedge fund recently raised its stake in Strata Skin Sciences stock. Azzad Asset Management Inc. ADV increased its stake in Strata Skin Sciences, Inc. (NASDAQ:SSKN) by 81.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,800 shares of the medical device company’s stock after acquiring an additional 9,800 shares during the period. Azzad Asset Management Inc. ADV owned approximately 0.41% of Strata Skin Sciences worth $45,000 at the end of the most recent reporting period. Institutional investors own 32.43% of the company’s stock.

Strata Skin Sciences Trading Down 3.5%

NASDAQ:SSKN traded down $0.01 on Friday, reaching $0.25. 9,308 shares of the company’s stock were exchanged, compared to its average volume of 666,269. The firm has a market capitalization of $1.47 million, a price-to-earnings ratio of -0.09 and a beta of 0.33. Strata Skin Sciences has a 52-week low of $0.12 and a 52-week high of $3.86. The company has a quick ratio of 0.75, a current ratio of 0.95 and a debt-to-equity ratio of 10.22. The business has a fifty day moving average of $1.02 and a 200-day moving average of $1.46.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on SSKN shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Strata Skin Sciences in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Strata Skin Sciences from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Strata Skin Sciences Company Profile

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.